Status:
COMPLETED
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Lead Sponsor:
University of Milano Bicocca
Conditions:
COVID
Pneumonia, Viral
Eligibility:
All Genders
18-80 years
Brief Summary
Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive...
Detailed Description
SARS-CoV-2 related disease started in December 2019 in the Chinese city of Wuhan, rapidly spread and became an international health emergency. Pneumonia is a frequent element of COVID-19, its pathoge...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 80 years
- Able to sign informed consent to participate in the study
- Real time PCR diagnosis od SARS-CoV-2 infection
- Hospital admission due to clinical/instrumental diagnosis of interstitial pneumonia
- Presence of acute respiratory failure (PaO2/FiO2 \<300 mm Hg) at the moment of hospital admission
Exclusion
- Severe renal failure defined as glomerular filtration rate (GFR) \< 30 ml/min at hospital discharge
- Cardiovascular failure NYHA class IV (patient unable to perform any activity) at hospital discharge
- Active solid or hematological malignancies at hospital discharge
- Prior diagnosis of chronic obstructive pulmonary disease (COPD), pulmonary emphysema, pulmonary fibrosis, bronchiectasis associated or not associated to cystic fibrosis
- Pregnancy or breastfeeding
- Suspected bacterial or fungine pulmonary superinfection during hospital stay
Key Trial Info
Start Date :
October 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 18 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04435327
Start Date
October 5 2020
End Date
March 18 2022
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Gerardo Hospital
Monza, MB, Italy, 20900